Biopharma vendors love to talk about science. But the real battlefield—especially in Europe—is procurement.
When a drug approaches loss of exclusivity (LoE), the market doesn’t just “open.” It gets contested. Tendering becomes the mechanism through whi…

Biopharma is entering a new kind of “patent cliff” moment—not just in R&D, but in the way products are packaged, tracked, and sold.
For years, the industry has treated serialization and anti-counterfeit as compliance necessities. But as loss of exc…

One-shot: How to pick the right drug patent for maximum term-extension value
In pharma, timing is destiny—and patent term extension is where strategy meets arithmetic.
Most companies treat patent selection as a legal exercise. But when you’re trying to…

Drug patent litigation isn’t just about molecules—it’s about design choices.
In the pharmaceutical world, “design-around” is often discussed like a high-level strategy. But the real work happens at the claim level: where formulation details, process …

Pharma executives don’t lose in Eurasia because they “missed a filing.”
They lose because they misunderstood the system.
Drug patents in Eurasia aren’t just a legal checklist item—they’re a moving target shaped by jurisdictional quirks, enforcement rea…

Pharmaceutical patent strategy is often discussed like a binary choice: fight or fold. But in practice, the real question is more uncomfortable—and more profitable:
Cut, keep, or cash.
That’s the core idea behind a decision matrix that separates “winni…